» Articles » PMID: 31137047

Z-ligustilide and N-Butylidenephthalide Isolated from the Aerial Parts of Angelica Tenuissima Inhibit Lipid Accumulation In Vitro and In Vivo

Overview
Journal Planta Med
Specialty Biology
Date 2019 May 29
PMID 31137047
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormal lipid metabolism, such as increased fatty acid uptake and esterification, is associated with nonalcoholic fatty liver disease (NAFLD). The aqueous extract of the aerial part of (ATX) inhibited high-fat diet-induced hepatic steatosis in mice as well as oleic acid-induced neutral lipid accumulation in HepG2 cells. ATX decreased the mRNA and protein levels of CD36 and diglyceride acyltransferase 2 (DGAT2), the maturation of sterol regulatory element-binding proteins (SREBP), and the expression of the lipogenic target genes and . The ATX components, Z-ligustilide and n-butylidenephthalide, inhibited the expression of FATP5 and DGAT2 and thus oleic acid-induced lipid accumulation in HepG2 cells. These results suggest that ATX and its active components Z-ligustilide and n-butylidenephthalide inhibit fatty acid uptake and esterification in mice and have potential as therapeutics for NAFLD.

Citing Articles

Z-Ligustilide: A Potential Therapeutic Agent for Atherosclerosis Complicating Cerebrovascular Disease.

Shen L, Tian Q, Ran Q, Gan Q, Hu Y, Du D Biomolecules. 2025; 14(12.

PMID: 39766330 PMC: 11726876. DOI: 10.3390/biom14121623.


Antiviral Activity of Angelica Tenuissima Nakai against Influenza A Virus.

Park W, Bae G, Han Y Pathogens. 2024; 13(9).

PMID: 39338952 PMC: 11435179. DOI: 10.3390/pathogens13090761.


Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.

Fu Y, Wang Z, Qin H Metabolites. 2024; 14(4).

PMID: 38668346 PMC: 11052500. DOI: 10.3390/metabo14040218.


Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.

Feng Y, Sun W, Sun F, Yin G, Liang P, Chen S Drug Des Devel Ther. 2022; 16:3829-3845.

PMID: 36388082 PMC: 9642071. DOI: 10.2147/DDDT.S386982.


The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity.

Fu K, Wang C, Ma C, Zhou H, Li Y Front Pharmacol. 2021; 12:771459.

PMID: 34803712 PMC: 8600187. DOI: 10.3389/fphar.2021.771459.